Literature DB >> 3598828

Prevention of strabismic amblyopia of early onset with special reference to the optimal age for screening.

E Neumann, Z Friedman, B Abel-Peleg.   

Abstract

Of 78 consecutive cases with constant unilateral esotropia diagnosed during screening and treated from the ages of seven months to three years, 82% ended up with visual acuity of 6/12 or better toward end of active treatment at the age of six to eight years. Of the cases with visual acuity of 6/12 or better at the end of treatment, 59% retained their vision when re-examined four to ten years later. The most important single parameter for the achievement of normal visual acuity was age of onset of treatment below two years and for long-term stability of the result this age dropped to 18 months. Initial large angles of esotropia had better prognosis probably because they were associated with an earlier onset of treatment. Poor prognosis was associated with faulty or no fixation of the esotropic eye when first diagnosed, with the failure to achieve alternation and with marked ansiometry. The optimal age for screening for strabismic amblyopia was suggested to be 12-18 months.

Entities:  

Mesh:

Year:  1987        PMID: 3598828     DOI: 10.3928/0191-3913-19870501-03

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  3 in total

1.  Vision screening programs in children.

Authors:  K F Damji
Journal:  Can Fam Physician       Date:  1988-05       Impact factor: 3.275

2.  Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial.

Authors:  Prachee Vasant Pawar; Sachin S Mumbare; Mrunal Suresh Patil; Seema Ramakrishnan
Journal:  Indian J Ophthalmol       Date:  2014-02       Impact factor: 1.848

3.  Prevalence of amblyopia and its impact on the academic performance of male medical students in Southern Saudi Arabia.

Authors:  Khalid A Fayi; Dhafer S Alahmari; Dhafer S Alamri; Yahya H Al-Falki
Journal:  Saudi J Ophthalmol       Date:  2018-09-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.